News | August 06, 2023
Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
CMOs showed an increasing reluctance to take on debt in 2022
Subscribe To Our Newsletter & Stay Updated
